secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001104659-26-049787
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility
----------------------------------------------------------------------

- Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.
- Company reports ~$5.9M cash; evaluating strategic options including M&A or advancing dusquetide for Behçet's Disease.
- HyBryte previously showed statistically significant lesion reduction in Phase 3 FLASH study at 6 weeks, but not replicated in FLASH2.
- Soligenix plans further data analysis to identify patient subsets; will discuss with FDA and EMA if warranted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000110465926049787/0001104659-26-049787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000110465926049787/sngx-20260428x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-049787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer